The analysis of 11,427 Veterans Administration (VA) hospital patients with multiple myeloma (MM) reveals that lymphopenia affects 53% of patients at diagnosis. The median overall survival was 2.7 ...

Researchers conducted a retrospective study to examine the relationship between absolute lymphocyte count (ALC) trajectory and clinical outcomes, and the factors associated with lymphopenia in severe ...

A mixed methods evaluation of the Canopy Cancer Collective’s implementation of network-wide screening initiative in 2023.

Researchers sought to determine whether teclistamab would lead to a clinical response in patients with relapsed/refractory multiple myeloma.

The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...

The FDA’s move to lift the hold on Zentalis Pharmaceuticals’ sole clinical-stage drug may have been good news for the biotech—but it’s been bad news for some of its staff. | The FDA’s move to lift the ...

The addition of sintilimab to neoadjuvant chemoradiotherapy achieved a 60% pathological complete response rate vs 47.3% with chemoradiotherapy alone in locally advanced ESCC.

The trial is anticipated to enrol 462 subjects and aims to confirm the safety and efficacy of the combination.

In resectable, locally advanced esophageal squamous cell carcinoma, neoadjuvant Tyvyt plus chemoradiotherapy led to an ...

Community‐acquired respiratory viral infections are a severe risk for patients with hematological malignancies, particularly ...

Reduced systemic exposure of Abe minimized the incidence of lymphopenia and hepatic toxicity. In addition, researchers found that although Abe could upregulate expression of indoleamine 2 ...